GSK relocates 2,200 sales positions as part of 'growth strategy'

Share this article:
Witty: adding reps in emerging areas
Witty: adding reps in emerging areas
GlaxoSmithKline has put a twist on pharma's strategy of slashing sales reps to improve the earnings outlook, reallocating the positions to emerging markets.

Last year, the company announced a 12% reduction in sales forces.  In a third-quarter earnings presentation recapping the firm's return to top-line growth, CEO Andrew Witty said his company's growth strategy involves shifting some of those US and European sales roles over to Asia-Pacific and emerging markets.

“Just over the last year or so,” the chief executive said in a Web video, “we've reduced by around 2,200 the number of sales personnel in our established western markets, and we've increased by around 2,200 the number of sales personnel in our emerging and Asia-Pacific markets—that's a good example of how we are reallocating resources to go for growth.”

The shifts are reflected in quarterly sales, up 3% overall, 25% in emerging markets and 19% in Japan.  That's due to growth in pandemic flu vaccine and anti-viral Relenza, which is getting more government orders for swine flu, along with devices.

Meanwhile, growth is moderating in mature regions.  Less than a third of total sales came from the “small white pills/Western markets” of the US and Europe, the company said.

The company is also executing on its pipeline.  In the last two weeks, it has received FDA approvals for cervical cancer vaccine Cervarix, oncology drug Votrient and Arzerra for oncology and rheuatmoid arthritis.  Recent data on lupus drug Benlysta, with partner Human Genome Sciences, also look interesting.

As Witty sees it, simplifying the business model will remain a strong focus:  “We continue to look for ways to drive greater efficiency and disinvest in areas which we believe no longer serve us well."
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...